FDA's new guidance clarifies promotional practices for biosimilars, ensuring accurate marketing and preventing misleading ...
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Explore the cost-effectiveness of ranibizumab biosimilars versus aflibercept in treating AMD and DME, revealing significant ...
November 2025 highlights FDA approvals for denosumab and pertuzumab biosimilars, enhancing competition and access in oncology and bone health markets.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.
Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP ...
Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...
Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...
Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...
Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback